AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthesia: Dibucaine belongs to the class of medications known as local anesthetics, which work by blocking nerve signals in a specific area of the body, leading to temporary loss of sensation or pain relief. Dibucaine is used to provide local anesthesia for minor surgical procedures, dental procedures, and medical interventions involving the skin, mucous membranes, or other superficial tissues.
Topical Application: Dibucaine is most commonly administered topically as a cream, ointment, gel, or solution that is applied directly to the skin or mucous membranes to numb the area before a procedure or to relieve pain or itching associated with minor skin conditions such as insect bites, minor burns, cuts, abrasions, or hemorrhoids.
Analgesic Effects: Dibucaine provides temporary pain relief by blocking the transmission of pain signals from sensory nerves to the brain. It can help alleviate discomfort and pain associated with minor injuries, skin irritations, or medical procedures, allowing patients to undergo treatment or perform activities with greater comfort.
Anti-Itch Properties: In addition to its analgesic effects, dibucaine has mild anti-itch properties that can help relieve itching and irritation associated with insect bites, allergic reactions, dermatitis, or other inflammatory skin conditions. Dibucaine may be used alone or in combination with other medications to provide relief from itching and discomfort.
Onset and Duration of Action: Dibucaine typically has a rapid onset of action, with numbing effects occurring within minutes after application to the skin or mucous membranes. The duration of action varies depending on factors such as the concentration of dibucaine, the site of application, and individual patient factors, but generally lasts for several hours before wearing off.
Side Effects: While generally safe when used as directed, dibucaine can cause local side effects such as skin irritation, redness, swelling, or allergic reactions in some individuals. Prolonged or excessive use of dibucaine or application to large areas of the body may increase the risk of systemic side effects such as systemic toxicity or allergic dermatitis.
Contraindications: Dibucaine is contraindicated in individuals with a known hypersensitivity or allergy to the medication or any of its components. It should not be applied to broken or inflamed skin, mucous membranes, or areas with impaired barrier function, as this may increase the risk of systemic absorption and adverse effects.
Interactions: Dibucaine may interact with other medications or substances, including other local anesthetics, that affect the nervous system or cardiovascular function. It's important for individuals using dibucaine to inform their healthcare provider about all other medications, supplements, or topical products they are using to avoid potential interactions or adverse effects.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Morganellaceae | family | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
1 | 0 | Proteus | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Leishmania | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | unclassified Proteus (in: enterobacteria) | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
0 | 1 | Proteus mirabilis | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
0 | 1 | Proteus genomosp. 6 | species | Decreases |
0 | 1 | Proteus hauseri | species | Decreases |
0 | 1 | Proteus myxofaciens | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
0 | 1 | Proteus vulgaris | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
0 | 1 | Proteus terrae | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
0 | 1 | Proteus columbae | species | Decreases |
0 | 1 | Proteus penneri | species | Decreases |
0 | 1 | Leishmania donovani species complex | species group | Decreases |
0 | 1 | Leishmania major species complex | species group | Decreases |
0 | 1 | Leishmania mexicana species complex | species group | Decreases |
1 | 0 | Leishmania | subgenus | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
Acne | 0.3 | 0.3 | |
ADHD | 1.4 | 1.4 | |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
Allergic Rhinitis (Hay Fever) | 1.3 | 0.4 | 2.25 |
Allergies | 2 | 0.6 | 2.33 |
Allergy to milk products | 0.7 | 1.3 | -0.86 |
Alopecia (Hair Loss) | 1.1 | 1.1 | |
Alzheimer's disease | 2.4 | 2 | 0.2 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.4 | 1 |
Ankylosing spondylitis | 1.9 | 0.6 | 2.17 |
Anorexia Nervosa | 0.4 | 1.1 | -1.75 |
Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
Asthma | 1.8 | 0.8 | 1.25 |
Atherosclerosis | 2.2 | 1 | 1.2 |
Atrial fibrillation | 1 | 1.6 | -0.6 |
Autism | 2.7 | 4.5 | -0.67 |
Autoimmune Disease | 0.6 | 0.5 | 0.2 |
Barrett esophagus cancer | 0.3 | 0.3 | |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1 | 1 | |
Bipolar Disorder | 1.6 | 0.5 | 2.2 |
Brain Trauma | 0.5 | 0.8 | -0.6 |
Breast Cancer | 0.5 | 0.5 | 0 |
Cancer (General) | 0.3 | 0 | 0 |
Carcinoma | 2 | 0.7 | 1.86 |
Celiac Disease | 1.4 | 1 | 0.4 |
Cerebral Palsy | 0.3 | 0.8 | -1.67 |
Chronic Fatigue Syndrome | 1.1 | 1.8 | -0.64 |
Chronic Kidney Disease | 1.3 | 0.8 | 0.63 |
Chronic Lyme | 0.8 | -0.8 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.8 | -0.14 |
Chronic Urticaria (Hives) | 1 | 0.3 | 2.33 |
Coagulation / Micro clot triggering bacteria | 1.4 | 0.5 | 1.8 |
Cognitive Function | 1.3 | 0.5 | 1.6 |
Colorectal Cancer | 3.4 | 1.5 | 1.27 |
Constipation | 1.1 | 0.5 | 1.2 |
Coronary artery disease | 1 | 1.1 | -0.1 |
COVID-19 | 2.9 | 1.5 | 0.93 |
Crohn's Disease | 4.7 | 1.8 | 1.61 |
Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
cystic fibrosis | 1 | 0.8 | 0.25 |
d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
deep vein thrombosis | 2.4 | 0.8 | 2 |
Denture Wearers Oral Shifts | 0.1 | 0.1 | |
Depression | 4.1 | 2.7 | 0.52 |
Eczema | 0.9 | 0.3 | 2 |
Endometriosis | 1.7 | 0.9 | 0.89 |
Eosinophilic Esophagitis | 0.3 | 0.3 | |
Epilepsy | 1.8 | 1.3 | 0.38 |
erectile dysfunction | 1.2 | 1.2 | |
Fibromyalgia | 1.6 | 0.4 | 3 |
Functional constipation / chronic idiopathic constipation | 2.5 | 1.5 | 0.67 |
gallstone disease (gsd) | 2.2 | 0.8 | 1.75 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.9 | |
Generalized anxiety disorder | 1.6 | 0.8 | 1 |
Gout | 0.3 | 0.3 | |
Graves' disease | 0.7 | 0.8 | -0.14 |
Gulf War Syndrome | 0.3 | -0.3 | |
Halitosis | 0.7 | 0.7 | |
Hashimoto's thyroiditis | 1.4 | 0.6 | 1.33 |
Heart Failure | 1.8 | 0.5 | 2.6 |
hemorrhagic stroke | 0.7 | 0.7 | |
Hidradenitis Suppurativa | 1.4 | 1.4 | |
High Histamine/low DAO | 2.2 | 2.2 | |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
hyperglycemia | 1 | 0.7 | 0.43 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 1.9 | 1.4 | 0.36 |
Hypothyroidism | 0.5 | 0.5 | |
Hypoxia | 1.7 | 1.7 | |
IgA nephropathy (IgAN) | 1 | 0.7 | 0.43 |
Inflammatory Bowel Disease | 3.1 | 2.7 | 0.15 |
Insomnia | 0.3 | 0.8 | -1.67 |
Intelligence | 0.8 | 0.8 | |
Intracranial aneurysms | 1 | 1 | |
Irritable Bowel Syndrome | 2.7 | 1.6 | 0.69 |
ischemic stroke | 1.1 | 1.4 | -0.27 |
Liver Cirrhosis | 3.1 | 1.8 | 0.72 |
Long COVID | 2.4 | 1.8 | 0.33 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.9 | 0.9 | |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.7 | 0.7 | |
ME/CFS with IBS | 0.3 | -0.3 | |
ME/CFS without IBS | 0.9 | -0.9 | |
Menopause | 0.5 | -0.5 | |
Metabolic Syndrome | 3.1 | 2.5 | 0.24 |
Mood Disorders | 3.4 | 2.5 | 0.36 |
Multiple Sclerosis | 2.4 | 2.1 | 0.14 |
myasthenia gravis | 0.6 | 0.5 | 0.2 |
neuropathic pain | 1.3 | -1.3 | |
Neuropathy (all types) | 1.6 | -1.6 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 1.3 | 0.62 |
NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
Obesity | 3.9 | 2 | 0.95 |
obsessive-compulsive disorder | 2.3 | 0.3 | 6.67 |
Osteoarthritis | 1 | 0.3 | 2.33 |
Osteoporosis | 1.4 | 0.3 | 3.67 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 3.8 | 2.5 | 0.52 |
Polycystic ovary syndrome | 3.8 | 1.1 | 2.45 |
Premenstrual dysphoric disorder | 0.4 | -0.4 | |
primary biliary cholangitis | 0.4 | -0.4 | |
Primary sclerosing cholangitis | 1.5 | 1 | 0.5 |
Psoriasis | 0.6 | 1.9 | -2.17 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.3 | 1.4 | 1.36 |
Rosacea | 0.5 | -0.5 | |
Schizophrenia | 1.4 | 1.3 | 0.08 |
scoliosis | 0.9 | 0.3 | 2 |
sensorineural hearing loss | 0.5 | 0.5 | |
Sjögren syndrome | 1 | 0.8 | 0.25 |
Sleep Apnea | 0.3 | 0.8 | -1.67 |
Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 1.5 | |
Stress / posttraumatic stress disorder | 1.9 | 1.3 | 0.46 |
Systemic Lupus Erythematosus | 2.1 | 0.8 | 1.63 |
Tic Disorder | 0.3 | 0.3 | |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 1.7 | 1.1 | 0.55 |
Type 2 Diabetes | 3.6 | 2.6 | 0.38 |
Ulcerative colitis | 2.9 | 2.2 | 0.32 |
Unhealthy Ageing | 1.5 | 1 | 0.5 |
Vitiligo | 1 | 0.4 | 1.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]